Research programme: drug discovery - Janssen/Johnson &Johnson Innovation/MaRS Innovation
Latest Information Update: 19 Dec 2013
At a glance
- Originator Janssen Inc; Johnson & Johnson; MaRS Innovation
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified
Most Recent Events
- 25 Nov 2013 Early research in Undefined indication in Canada (unspecified route)